Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

 
Press Releases
  Date Title View
Nov 14, 2016
Mateon Provides Corporate Update and Reports Third Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the third quarter of 2016. Recent Corporate Hig...

Nov 11, 2016
Mateon Announces Adjournment of Special Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the special meeting of stockholders scheduled for today has been adjourned, with the adjournment its...

Oct 31, 2016
Mateon Announces Presentation of CA4P Posters at Meeting of the International Gynecologic Cancer Society

- Patients with Measurable Disease Showed Significantly Improved Progression-Free Survival - - Progression-Free Survival Improved by 6.2 Months for Patients with Larger Tumors - SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting a...

Oct 27, 2016
Mateon Expands Board of Directors with the Appointments of Donald R. Reynolds and Bobby W. Sandage, Jr., Ph.D.

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced the appointment of two new members to its board of directors. Effective October 25, 2016, Donald R. Reyno...

Oct 10, 2016
Mateon Announces Issuance of US Patent for Cathepsin Inhibition

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,458,103 to Mateon and Baylor Universit...

Sep 26, 2016
Mateon Announces Collaboration with US Oncology Research to Participate in Phase 2/3 FOCUS Study

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced a collaboration under which sites affiliated with US Oncology Research will participate in the FOCUS Stu...

Sep 20, 2016
Mateon Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will present an overview of the company at the Ladenburg Thalmann 2016 Healthcare Conference ...

Sep 7, 2016
Mateon Therapeutics to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York on September 12, 2016

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investmen...

Aug 3, 2016
Mateon Provides Corporate Update and Reports Second Quarter 2016 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the second quarter of 2016. Recent Corporate ...

Jul 21, 2016
Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the first patient has been enrolled into the Phase 2 portion of the PAZOFOS Study. The PAZOFOS Study...

1
...
NextLast
= add release to Briefcase